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Oxidation-reduction properties of eleven gold(III) complexes with (S,S)-R2edda-type ligands was 
studied by cyclic and differential pulse voltammetry in DMSO. Series I: [AuCl2{(S,S)-R2eddip}]PF6, 
(S,S)-eddip = (S,S)-ethylenediamine-N,N’-di-2-propanoate, R =  n-butyl, n-pentyl, isobutyl, isoamyl, 
cyclopentyl, 1–5; II: [AuCl2{(S,S)-R2eddch}]PF6, (S,S)-eddch = (S,S)-ethylenediamine-N,N’-di-2-(3-
cyclohexyl)propanoate, R = methyl, ethyl, n-propyl, n-butyl, isobutyl, isoamyl, 6–11. Voltammograms 
in DMSO showed two successive irreversible reduction steps, where Au
I
 species were the final 
reduction product. Reduction potential values are in range from 116 to 156 mV (Ep1) and –520 to –572 
mV (Ep2) for Series I and from 148 to 228 mV (Ep1) and –569 to –638 mV (Ep2) for Series II. In 
general, slightly easier reduction of complexes belonging to Series I (higher cytotoxicity) could be due 
to less steric hindrance around the gold center. Reduction potentials and anticancer activity are not in 
correlation.  
 
 
Keywords: gold(III) complexes; R2edda-type ligands; anticancer activity; reduction potential; 
voltammetry. 
 
 
 
1. INTRODUCTION 
The therapeutic value of metal-based drugs has been well established [1-5]. The first metal-
based anticancer drug discovered is cisplatin [6]. Its anticancer effect might be due to covalently 
binding to DNA forming adducts that interfere with transcription and DNA replication, and thereby 
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triggers programmed cell death [7-9]. However, severe side effects such as nephrotoxicity, ototoxicity 
and neurotoxicity, and the development of resistance are drawbacks which lead to increased 
motivation for alternative chemotherapeutic strategies [10-14]. 
Due to the structural similarity of gold(III) and platinum(II) complexes, it was believed that the 
mechanism of action for gold(III) compounds might also be DNA binding and disruption of DNA 
replication [15,16]. However, recent findings by Messori et al. showed that most of the cytotoxic 
gold(III) complexes have a weaker binding affinity for DNA than cisplatin [17-19]. Subsequent studies 
have suggested that the therapeutic effect of gold compounds may arise from interactions with 
different proteins [17,18]
 
such as the mitochondrial enzyme thioredoxin reductase (TrxR) [20], the 
proteasome [21], cystein proteases [22] as well as human serum albumin (HSA), human glutathione 
reductase and protein tyrosine phosphatases [23]. Moreover, gold(III) complexes were found to be 
responsible for inhibition of zinc finger PARP-1-protein (PARP = poly(adenosine diphosphate-ribose) 
polymerase [24].  
It is important to note that for almost all known active gold(III) complexes, the active 
metabolites could be gold(I) species produced by gold(III) reduction in vivo [25]. Reduction potential 
values are an unavoidable parameter in establishing the mode of action since most 
metallopharmaceuticals are activated by in vivo electron transfer [26]. 
 
 
 
Figure 1. Structure formulae of the studied gold(III) complexes. 
 
In this paper, the aim is to contribute to structure-activity relationships, and as a part of our 
investigations of the physical and structural parameters of gold(III) complexes, we have studied the 
electrochemical behavior of eleven gold(III) complexes within two Series of (S,S)-R2edda-type 
ligands: I - [AuCl2{(S,S)-R2eddip}]PF6, ((S,S)-eddip = (S,S)-ethylenediamine-N,N’-di-2-propanoate, 
R = n-butyl (n-Bu), n-pentyl (n-Pe), isobutyl (i-Bu), isoamyl (i-Am) and cyclopentyl (cPe); 1–5, 
respectively) and II - [AuCl2{(S,S)-R2eddch}]PF6, ((S,S)-eddch = (S,S)-ethylenediamine-N,N’-di-
2-(3-cyclohexyl)propanoate, R = methyl (Me), ethyl (Et), n-propyl (n-Pr), n-butyl (n-Bu), isobutyl 
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(i-Bu) and isoamyl(i-Am); 6–11, respectively) shown in Figure 1. The electrochemical data may be 
helpful in constructing structure-activity relationships. The synthesis, characterization and biological 
activity of these gold(III) complexes have recently been published [27,28]. 
 
 
2. EXPERIMENTAL 
2.1. Materials and methods 
Dimethyl sulfoxide (DMSO) and LiClO4 were purchased (Aldrich, USA) and used without 
further purification. All complexes (1−11) were dissolved in DMSO in the concentration of 1.0 mM, 
followed by addition of 0.01 M LiClO4 as a supporting electrolyte. 
Electrochemical measurements were performed at ambient temperature using CHI-760B 
potentiostat (CHI Instruments, USA) for cyclic voltammetry and differential pulse voltammetry. The 
voltammetric measurements were performed in a three-electrode cell containing a platinum working 
electrode (Model 6.1204.120), a non-aqueous Ag/AgCl reference electrode (Model CHI 112) and a 
platinum wire as counter electrode (model CHI 115). Reduction potentials of all compounds were 
determined by differential pulse voltammetry. The obtained electrochemical data are shown in Table 1. 
 
2.2. Complexes 
Complexes 1−11 were synthesized and fully characterized in our recent publications [27,28]. 
Explicitly, gold(III) complexes 1−5 were synthesized in the reaction of Na[AuCl4] with equimolar 
amount of corresponding ligand hydrochlorides, n-butyl, n-pentyl, isobutyl, isoamyl and cyclopentyl 
diesters of (S,S)-ethylenediamine-N,N’-di-2-propanoic acid, respectively [27]. Gold(III) complexes 
6−11 were synthesized in the reaction of Na[AuCl4] with an equimolar amount of corresponding 
ligand hydrochlorides, methyl, ethyl, n-propyl, n-butyl, isobutyl and isoamyl diesters of (S,S)-
ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoic acid resprectively [28]. Each ligand was 
suspended in methanol, deprotonated with LiOH∙H2O and after stirring of 1h, a solution of 
Na[AuCl4]∙2H2O in methanol was added. The desired complexes were obtained after addition of 
ammonium hexafluorophosphate. Purity and constitution of the obtained products were confirmed with 
elemental analysis, 
1
H and 
13
C NMR as well as UV/Vis spectroscopies and mass spectrometry. As 
examples for Series I and II analytical and spectroscopic data for complexes 4 and 11 are provided. 
 
2.3. Characterization of complexes 4 and 11 
Complex 4 [27]: [Yield 55 mg, 57%] Analysis: Calculated for C18H36N2O4AuCl2PF6∙H2O: C, 
27.88; H, 4.94; N, 3.61. Found: C, 27.44; H, 4.84; N, 3.43. 
1
H NMR (200 MHz, DMSO-d6): 0.92 (d, 
12H, (CH3)2CHCH2CH2−OOC−), 1.61 (m, 10H, (CH3)2CHCH2CH2−OOC−, CH3), 1.73 (m, 2H, 
(CH3)2CHCH2CH2−OOC−), 3.76 (d, 4H, CH2-(en)), 3.82 (s, 2H, NH), 4.11 (d, 2H, CH), 4.31 (m, 4H, 
(CH3)2CHCH2CH2−OOC−). 
13
C NMR (50 MHz, DMSO-d6): 14.9 (CH3)2CHCH2CH2−OOC−), 16.2 
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(CH3), 22.3 (CH3)2CHCH2CH2−OOC−), 24.9 (CH3)2CHCH2CH2−OOC−), 36.8 (CH2-(en)), 56.1 (CH), 
66.3 (CH3)2CHCH2CH2−OOC−), 169.5 (CH3)2CHCH2CH2−OOC−). ESI–MS in CH3CN: m/z 612.17 
[M]
+
. IR / cm
-1
 (ATR): 2961m, 2873m, 1739vs, 1461s, 1227s, 849w, (vs, very strong; s, strong; m, 
medium; w, weak).. UV-visible in CHCl3 [max/nm]: 322.  
Complex 11 [28]: [Yield 66 mg, 57%] Analysis: Calculated for C30H56N2O4AuCl2PF6: C, 
39.09; H, 6.12; N, 3.04. Found: C, 38.98; H, 6.13; N, 3.11. 
1
H NMR (200 MHz, CDCl3): δ 0.95 (d, 
(CH3)2CHCH2CH2–OOC–, 12H; m, C
7
H2, 4H), 1.24 (m, C
5,6
H2, 8H), 1.50-1.90 (m, C
3
H2, C
4
H, C
5,6
H2, 
(CH3)2CHCH2CH2–OOC– and (CH3)2CHCH2CH2–OOC–, 20H), 3.43 (m, C
8
H2, 4H), 3.92 (m, C
2
H, 
2H), 4.30 (m, (CH3)2CHCH2CH2–OOC–, 4H), 4.71 (s, NH, 2H). 
13
C NMR (50 MHz, CDCl3): δ 11.1 
((CH3)2CHCH2CH2–OOC–), 16.3 ((CH3)2CHCH2CH2–OOC–), 22.3 ((CH3)2CHCH2CH2–OOC–), 25.9 
(C
6
), 32.4 (C
4
), 33.1 (C
7
), 33.8 (C
5
), 36.9 (C
3
), 44.5 (C
8
), 59.2 (C
2
), 65.8 ((CH3)2CHCH2–OOC–), 
171.0 (C
1
). ESI–MS in CH3CN: m/z 775.33 [M]
+
, 776.33 [M + H]
+
. IR / cm
-1
 (ATR): νmax = 2929m, 
2854m, 1731vs, 1453s, 1260s, 1212s, 851w (vs, very strong; s, strong; m, medium; w, weak). UV-
visible in CHCl3 [max/nm (/ M
-1
 cm
-1
)]: 320 (6630).  
 
 
 
3. RESULTS AND DISCUSSION 
3.1. Electrochemical behavior 
3.1.1. Gold(III) complexes with (S,S)-R2eddip ligands, Series I: 1−5 
 
Figure 2. Cyclic voltammograms of 1.0 mM solutions of 1−5 in DMSO with LiClO4. Scan rate 0.1 
V/s. 
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The inherent electrochemical properties of the investigated gold(III) complexes with (S,S)-
R2eddip ligands were studied by cyclic voltammetry immediately after dissolution (Figure 2). On a 
clean platinum surface, in DMSO, complexes 1−5, exhibit two successive irreversible reduction steps 
accompanied by the loss of chlorido ligands. The reduction potential values are in the range from 116 
to 156 mV (Ep1) and from − 520 to − 572 mV (Ep2). The first step is probably a one-electron process, 
[NN’-AuCl2]
+
 + e
−
 → [NN’-AuCl]+ + Cl‾ , whereas the second is [NN’-AuCl]+ + e− → [NN’-Au] + + Cl‾  
(NN’ presents ligand) . For all complexes the two peaks imply a short-living AuII intermediate in the 
reduction, whose exact chemical composition (either AuCl
+
 as given above or some dimer) is not clear 
at this stage [29]. Due to the absence of metallic gold at the platinum working electrode, we can 
conclude that overall reduction does not lead to Au
0
 but rather to Au
I
 species. This observation was 
also confirmed by potentiostatic reduction at –0.8 V vs. Ag/AgCl ref. electrode for 15 min. 
There is no strong correlation between reduction potential and the length of the alkyl ester 
chains in complexes 1–5. Furthermore, the potential differences between the first and second reduction 
peak remain approx. constant and this might demonstrate the same reduction pathway/mechanism.  
Two peaks of similar height with the potentials of around 0.12 V vs. Ag/AgCl and around 
−0.57 V vs. Ag/AgCl can be spotted using differential pulse voltammetry (Figure 3.). The length of 
alkyl chain in ligand didn’t significantly influence the reduction potential value.  
 
 
Figure 3. Differential pulse voltammograms of 1.0 mM solutions of 1−5 complexes in DMSO with 
LiClO4. Modulation amplitude 0.05 V, modulation time 0.04 s.  
 
3.1.2. Gold(III) complexes with (S,S)-R2eddch ligands, Series II:  6−11 
As observed for 1−5, AuIII/AuI reduction of complexes 6−11 is also a two-step process (Figure 
4). In DMSO at the platinum electrode complexes have shown a reduction peak in the range from 148 
Int. J. Electrochem. Sci., Vol. 11, 2016 
  
1167 
to 228 mV (Ep1) and from −569 to −638 mV (Ep2). An irreversible two-electron process followed by 
the loss of the chlorido ligands is found as for Series I, but in this case the reduction process is more 
difficult (Figure 5). The main reason for this behavior could be found in the steric surrounding of the 
gold center, which is more pronounced in Series II than in I due to the presence of cyclohexyl moiety. 
The occurrence of the Au
III
/Au
0
 reduction is rejected due to lack of elemental gold at the platinum 
electrode.  
 
Figure 4. Cyclic voltammograms of 1.0 mM solutions of 6−11 in DMSO with LiClO4 at the scan rate 
of 0.1 V/s. 
 
 
Figure 5. Differential pulse voltammograms of 1.0 mM solutions of 6−11 complexes in DMSO with 
LiClO4. Modulation amplitude 0.05 V, modulation time 0.04 s. 
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In the cyclic voltammograms of 10, the observed signals originate from the oxidation/reduction 
process of the corresponding complex. At the experimental conditions, three reduction and two 
oxidation peaks were recorded, which all have good linearity of peak current with the square root of 
ascending scan rate (Figure 6). Shifts in peak potential were not significant. This phenomenon 
indicates diffusion controlled process of soluble species rather than adsorption to the electrode surface 
[30,31].
 
 
 
 
 
Figure 6. Cyclic voltammograms of 1.0 mM solutions of 10 in DMSO with  LiClO4 at the scan rates 
of 0.1, 0.3, 0.5 V/s using platinum electrode. A) and B) figures present dependence of the peak 
currents from the square root of the scan rate for the cathodic and anodic peaks. 
 
3.2. Correlation between redox potentials and biological activity 
Gold(III) complexes have high reduction potentials and fast rates of hydrolysis, thus they might 
be unstable under physiological conditions, which is opposite to platinum(II) analogues [32]. 
When polydentate ligands were used, the reduction potential of the metal center was lowered 
which led to reporting a large number of gold(III) complexes that are quite stable in physiological 
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medium, and manifest very promising antitumor activity against different human tumor cell lines, both 
in vitro and in vivo [33-36]. Even though mechanistic studies show that apoptosis is induced in tumor 
cells by the majority of cytotoxic gold complexes, the actual modes of action are still not completely 
identified. 
As it can be seen in Table 1, the most active gold(III) complexes toward HeLa (cervix 
adenocarcinoma), K562 (myelogenous leukemia) cell lines are those with less bulky ligands, i.e.  
Series I. Gold(III) complexes from both Series, I and II, have very similar Ep values, and are easily 
reduced to gold(I) species, thus could be good candidates for further investigations, especially complex 
2. In our study, a correlation between reduction potentials and biological activity was not detected. 
Reduction potentials do not play crucial role in modulation of the anticancer activity of gold(III) 
complexes within Series I and II, and in accordance to previous results with platinum(IV) and similar 
ligand systems [37], no relationship between reduction potential and IC50 values is observed. But in 
literature these investigations gave some results, and for platinum complexes it was found that the 
lower IC50 values were, the easier the reduction of  the examined class of compounds was (and also an 
increase of the reduction potential as the electron-withdrawing power of the axial ligands rises)  
[38,39]. In this case, most probably, the activity magnitude is related to the substituents in both ester 
moieties as well as in the side chain of aminocarboxylato backbone.   
 
Table 1. Comparative biological and electrochemical data 
 
Compound 
          IC50/ μM
a
 
HeLa            K562 Ep1/mV
b 
Ep2/mV
b
 
1 2.07
c
 2.97
c
                124 -544 
2 1.61
c
 1.45
c
                128 -568 
3 1.99
c
 4.41
c
                156 -520 
4 2.14
c
 5.01
c
                116 -572 
5 1.72
c
 5.54
c
                127 -570 
6 29.03
d
 15.03
d
 218 -595 
7 16.76
d
 8.35
d
  198 -569 
8 20.34
d
 7.77
d
                191 -569 
9 16.97
d
 12.05
d
                187 -638 
10 17.74
d
 10.73
d
                228 -608 
11 26.35
d
 3.76
d
                148 -578 
cisplatin 4.47 5.77 - - 
a
IC50 is the in vitro cytotoxic activity against HeLa (cervix adenocarcinoma) and K562 (myelogenous 
leukemia) cell lines in μM. 
b
Ep are reduction potential values determined using differential potential voltammetry. 
c
See literature
 
[27] 
d
See lirerature [28] 
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4. CONCLUSIONS 
Eleven gold(III) complexes, Series I: [AuCl2{(S,S)-R2eddip}]PF6, Series II: [AuCl2{(S,S)-
R2eddch}]PF6, with (S,S)-R2edda-type ester ligands are investigated by cyclic voltammetry and 
differential pulse voltammetry in DMSO. For both Series, I and II, the following is found  
- Reduction to Au
I
 species in two steps and through Au
II
 short-living intermediates occur. The 
two one-electron processes are accompanied with loss of chlorido ligands.  
- No elemental gold deposition at the platinum working electrode also indicates reduction to 
Au
I
 compounds. 
- Complexes from Series I have less bulky surroundings of the gold center, and are, in general, 
slightly easier to reduce. 
- Reduction potentials are not in dependence of the number of carbon atoms in ester chains.  
- No correlation of reduction potential and anticancer activity is found. 
Reduction potentials do not play crucial role in modulation of the anticancer activity of these 
gold(III) complexes. 
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